Improving muscle repair for Becker Muscular Dystrophy
Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy
This study is testing a new protein treatment designed to help repair muscle cells for people with Becker Muscular Dystrophy, with the hope of improving muscle function and easing symptoms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myofinity Biosciences INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11005455 on NIH RePORTER |
What this research studies
This research focuses on developing a new protein therapy aimed at enhancing the repair of muscle cell membranes in patients with Becker Muscular Dystrophy (BMD). The approach involves engineering a modified version of a protein called rhMG53, which plays a crucial role in muscle cell membrane repair. By optimizing this protein's properties, the research aims to create a treatment that can restore muscle function and alleviate symptoms associated with BMD. The project will gather essential data to support the application for FDA approval of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Becker Muscular Dystrophy, particularly those experiencing muscle weakness and related symptoms.
Not a fit: Patients with other forms of muscular dystrophy or those without a diagnosis of Becker Muscular Dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves muscle function and quality of life for patients with Becker Muscular Dystrophy.
How similar studies have performed: Previous research has shown promise with similar protein therapies in treating muscular dystrophies, indicating a potential for success in this novel approach.
Where this research is happening
Boston, United States
- Myofinity Biosciences INC — Boston, United States (Active)
Researchers
- Principal investigator: Weisleder, Noah — Myofinity Biosciences INC
- Study coordinator: Weisleder, Noah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.